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Abstract
Drug-induced liver injury (DILI) is a frequent and dangerous adverse effect faced during preclinical and clinical drug therapy. 
DILI is a leading cause of candidate drug attrition, withdrawal and in clinic, is the primary cause of acute liver failure. 
Traditional diagnostic markers for DILI include alanine aminotransferase (ALT), aspartate aminotransferase (AST) and 
alkaline phosphatase (ALP). Yet, these routinely used diagnostic markers have several noteworthy limitations, restricting 
their sensitivity, specificity and accuracy in diagnosing DILI. Consequently, new biomarkers for DILI need to be identified.
A potential biomarker for DILI is cytokeratin-18 (CK18), an intermediate filament protein highly abundant in hepatocytes 
and cholangiocytes. Extensively researched in a variety of clinical settings, both full length and cleaved forms of CK18 
can diagnose early-stage DILI and provide insight into the mechanism of hepatocellular injury compared to traditionally 
used diagnostic markers. However, relatively little research has been conducted on CK18 in preclinical models of DILI. In 
particular, CK18 and its relationship with DILI is yet to be characterised in an in vivo rat model. Such characterization of 
CK18 and ccCK18 responses may enable their use as translational biomarkers for hepatotoxicity and facilitate management 
of clinical DILI risk in drug development. The aim of this review is to discuss the application of CK18 as a biomarker for 
DILI. Specifically, this review will highlight the properties of CK18, summarise clinical research that utilised CK18 to 
diagnose DILI and examine the current challenges preventing the characterisation of CK18 in an in vivo rat model of DILI.
Keywords Drug-induced liver injury (DILI) · Hepatotoxicity · Cytokeratin-18 (CK18) · Biomarker · In vivo
Introduction
Drug‑induced liver injury (DILI)
Drug-induced liver injury (DILI) was first described in the 
1960’s and was once considered a ‘penalty for progress’ 
(Popper et al. 1965). Today, DILI is a frequent and serious 
safety issue faced by clinicians, pharmaceutical companies 
and regulatory bodies. The liver plays a key role in first-pass 
metabolism and drug elimination, so it is often exposed to 
high drug concentrations. These factors are believed to be 
the predominant reasons why the organ is particularly sus-
ceptible to drug-induced injury (Atienzar et al. 2016).
DILI defines an array of drug-induced hepatocellular 
injuries ranging from acute or chronic hepatitis to acute liver 
failure and is referred to as either intrinsic or idiosyncratic 
(Alempijevic et al. 2017; Mayoral et al. 1999; O’Grady et al. 
1993). Intrinsic DILI is predictable and dose-dependent, 
with hepatocellular injury attributed to the pharmacologi-
cal or toxic properties of the drug (Alempijevic et al. 2017; 
McGill and Jaeschke 2019). Drugs such as acetaminophen 
(APAP) demonstrate intrinsic DILI, with hepatocellu-
lar injury following APAP overdose a result of excessive 
accumulation of APAP reactive metabolite N-acetyl-p-
benzoquinoneimine (NAPQI) (Alempijevic et al. 2017). In 
comparison, idiosyncratic DILI is more complex due to its 
non-dose-dependent and varied nature, commonly attrib-
uted to hypersensitivity reactions, metabolic mechanisms 
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of injury and patient genetic variation (Alempijevic et al. 
2017; Fisher et al. 2015; McGill and Jaeschke 2019). The 
preclinical and clinical diagnosis of DILI is reliant on tradi-
tionally used biomarkers.
Traditional biomarkers for DILI
The diagnostic principles for DILI remain unchanged from 
the 1960’s, with traditional biomarkers alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (ALP) and total bilirubin (TBIL) still routinely 
utilised to diagnose DILI (Alempijevic et al. 2017; Church 
and Watkins 2017; Robles-Diaz et al. 2014). These bio-
markers form the foundation of ‘Hy’s Law’ in which drug-
induced hepatocellular injury is defined as; the presence of 
a threefold or greater elevation above the upper normal limit 
(ULN) of ALT or AST compared to control, the elevation 
of TBIL > 2 times the ULN without initial evidence of chol-
estasis and, no pre-existing or underlying explanation for 
the elevation of ALT, AST and TBIL, such as viral hepati-
tis (US Food and Drug Administration 2009). ALP is also 
applied to identify cholestasis, although a significant ALP 
level indicative of cholestasis is not clearly defined (Watkins 
et al. 2008). Although heavily utilised, these traditional bio-
markers for DILI have many preclinical and clinical limita-
tions affecting their sensitivity, specificity and accuracy in 
diagnosing DILI.
The preclinical and clinical limitations of traditional 
biomarkers for DILI leave significant gaps 
in knowledge
A major preclinical limitation of traditional biomarkers for 
DILI faced during drug development is that ALT, AST and 
ALP are not specific to hepatocellular injury. In nonclini-
cal species, ALT levels > 3–5 times the ULN are indica-
tive of adverse hepatocellular injury, even in the absence 
of histological changes (US Food and Drug Administration 
2009). During clinical investigations, the US Food and Drug 
Administration (FDA) recommends the discontinuation of 
preclinical drug development when serum ALT or AST lev-
els reach > 8 of the ULN during treatment (US Food and 
Drug Administration 2009). Additionally, if serum ALT 
or AST levels are > 5 of the ULN for more than a 2-week 
period, with the appearance of fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, fever and/or rash 
in a clinical setting, the FDA also recommends discontinua-
tion of treatment (US Food and Drug Administration 2009). 
Although ALT, AST and ALP are predominately found in 
the liver, they are also found in the kidneys, heart, brain, 
skeletal muscle and red blood cells (Church and Watkins 
2017; Tajima et al. 2019). As such, increases in these bio-
markers may not be indicative of hepatocellular injury or 
DILI, but of other forms of toxicity, such as, rhabdomyolysis 
or myocardial damage (Church and Watkins 2017; Tajima 
et al. 2019). While increased levels of traditional biomarkers 
for DILI are coupled with physical symptoms as previously 
described, these physical symptoms may also be indicative 
of other toxicities. Additionally, it is known that individuals 
can experience transient, non-adverse, fluctuations in ALT, 
AST and ALP levels (Church and Watkins 2017; Tajima 
et al. 2019). Several drugs in preclinical development have 
been discontinued due to significant elevations in traditional 
serum biomarkers of hepatotoxicity with no clear pathophys-
iological evidence of hepatocellular injury (Church and Wat-
kins 2017; Tajima et al. 2019).
On the other hand, traditional biomarkers for DILI have 
also failed to identify some hepatoxic drugs prior to FDA 
approval and subsequent release to market. The FDA have 
withdrawn several drugs, such as bromfenac (non-steroidal 
anti-inflammatory), ebrotidine (H2-receptor antagonist) and 
troglitazone (PPAR activator), from market due to severe 
patient morbidity and mortality as a direct result of DILI 
(Hunter et al. 1999; Kohlroser et al. 2000). Notably, trogl-
itazone (brand name  Rezulin®, once prescribed for treat-
ment of type 2 diabetes) demonstrated ALT > 3 ULN in 1.9% 
of patients with no reports of acute liver failure or severe 
hepatocellular injury throughout clinical trials (Goldkind 
and Laine 2006; Kohlroser et al. 2000; Mayall and Banerjee 
2014). Mere months after its release to market, the FDA rec-
ommended monthly liver function tests following numerous 
reports of hepatic failure and liver transplantation in patients 
taking troglitazone (Aronson 2016; Kohlroser et al. 2000). 
Liver biopsies confirmed histopathological damage, such as 
necrosis and fibrosis, which subsided following cessation of 
troglitazone (Aronson 2016; Kohlroser et al. 2000). With 
reported cases of hepatic failure and liver transplantation 
steadily increasing, the FDA withdrew  Rezulin® in 2000 
due to the life threatening hepatoxicity associated with the 
drug (Aronson 2016; Goldkind and Laine 2006; Mayall and 
Banerjee 2014). A key challenge in the case of troglitazone 
was that although traditional diagnostic markers for DILI 
identified significant hepatocellular injury, they were unable 
to shed light on potential mechanisms driving the observed 
injury.
Traditional biomarkers for DILI also do not provide insight 
into the mechanism of hepatocellular injury, a limitation for 
both preclinical and clinical assessment of drugs. Increased 
ALT, AST and ALP enzymatic activity in circulation is a direct 
result of increased tissue breakdown, but this gives no indica-
tion of how that damage occurred (Church and Watkins 2017; 
Tajima et al. 2019). The biological mechanism of hepatocellu-
lar injury is dependent on the type of drug and includes, but is 
not limited to, mitochondrial toxicity, reactive metabolite gen-
eration and oxidation (Church and Watkins 2017; Tajima et al. 
2019). Initial hepatocellular injury may also be exacerbated, 
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with activation of the innate and adaptive immune responses 
leading to further hepatocellular damage, such as fibrosis and 
hepatitis (Church and Watkins 2017; Tajima et al. 2019). For 
the majority of hepatoxic drugs and especially during preclini-
cal drug development, the biological mechanism of hepatocel-
lular injury is relatively unknown or poorly understood. A key 
issue in the area of drug development is the ability to translate 
hepatotoxicity findings in preclinical species to the likely risk 
of DILI in humans. In the clinic, understanding the biological 
mechanism of hepatocellular injury could help the diagnosis 
and treatment of DILI, allowing targeted therapy to improve 
overall prognosis. For example, if the mechanism of hepatocel-
lular injury is identified to be predominately of an inflamma-
tory nature, a corticosteroid could be administered to reduce 
the likelihood of further hepatocellular damage. However, this 
approach relies on early diagnosis of DILI, which is challeng-
ing when relying on traditional biomarkers for DILI.
A major clinical limitation of traditional DILI biomark-
ers involves interpretation of Hy’s Law and the associated 
levels of ALT, AST and ALP upon which a patient is deter-
mined to have DILI. As previously discussed, due to the 
nature of ALT, AST, ALP and TBIL, Hy’s Law identifies 
patients at high risk of fatal DILI, which is approximately 
10% of all DILI cases (Robles-Diaz et al. 2014; Tajima et al. 
2019). Therefore, the majority of patients with early-stage 
DILI are not diagnosed in the clinic, and it is critical that 
patients with early-stage DILI are identified. This would not 
only enable rapid and effective intervention, but would also 
improve long-term prognosis. DILI due to acetaminophen 
(APAP) overdose is a well-recognised and a frequent exam-
ple of this. APAP associated hepatotoxicity is considered 
dose-dependent therefore, when used at therapeutic doses, 
it is considered safe and effective (FDA 2011). The FDA has 
limited the strength of APAP to 325 mg per tablet/capsule, 
in addition to assigning a ‘black box’ warning for severe 
hepatocellular injury to help protect consumers from APAP 
overdose (Babai et al. 2018; FDA 2014; Holt and Ju 2006). 
Despite these efforts, APAP overdose remains one of the 
primary causes of acute liver failure in the United States 
(Babai et al. 2018; Holt and Ju 2006; Larson et al. 2005). 
As approximately 50% of APAP overdose cases are unin-
tentional, early detection biomarkers for DILI would allow 
clinicians to identify APAP overdose early and administer 
N-acetylcysteine (NAC) to prevent serious or any further 
progression of hepatocellular injury (Babai et al. 2018; FDA 
2014; Holt and Ju 2006).
The issue at hand—new biomarkers for DILI need 
to be identified
Consequently, due to the current preclinical and clinical 
limitations of traditional biomarkers for DILI, new and 
improved biomarkers for DILI are required. Not only will 
they need to be more specific and sensitive in diagnosing 
DILI, particularly early-stage DILI, but will also need to 
provide insight into the mechanism of hepatocellular injury. 
Ideally, these new biomarkers would be deployed in both 
preclinical and clinical settings, and would need to fill the 
current gaps left by traditional biomarkers for DILI.
Cytokeratin-18 (CK18) is one of a handful of potential 
biomarkers for DILI. CK18 is found in the intermediate 
filaments of the liver and has been identified as a poten-
tial biomarker for DILI (Tajima et al. 2019). CK18 and its 
relationship with hepatocellular injuries, such as DILI, has 
been extensively investigated in multiple clinical settings. 
However, in vivo rat models of hepatotoxicity investigat-
ing potential biomarkers (such as miRNAs and glutamate 
dehydrogenase) for DILI have not included CK18 in their 
investigative panels (Bailey et al. 2012, 2018). This is due 
to the lack of good, quantitative assays which has contrib-
uted to the lack of qualification for CK18. It is important to 
characterise CK18 and its relationship with hepatotoxicity in 
in vivo rat models, as these are heavily used for preclinical 
drug development. Detecting a signal in preclinical testing 
that is also monitorable in the clinic would help guide clini-
cians through a drug’s development safely.
Therefore, this review will highlight the properties of 
CK18 that may help to fill current gaps in knowledge left by 
traditional biomarkers for DILI, provide a brief overview of 
recent clinical research and discuss the current challenges 
and limitations surrounding the characterisation of CK18 in 
an in vivo rat model of hepatotoxicity.
Cytokeratin‑18 (CK18)
The cellular location of CK18, also referred to as KRT18, 
and the cleavage patterns of the protein make it a potential 
biomarker for DILI. CK18 is a type-I intermediate filament 
protein highly concentrated in hepatocytes and cholangio-
cytes (epithelial cells of the bile duct), comprising 5% of 
total liver protein (Tajima et al. 2019; Uhlén et al. 2015). 
The acidic protein contains a central helical rod domain 
flanked by a N-terminal head and C-terminal tail region and 
is co-expressed with type-II intermediate filament protein 
cytokeratin-8 (CK8) (Omary et al. 2006; Schutte et al. 2004). 
CK8/CK18 heterodimers are a resilient and adaptable scaf-
fold for hepatocytes, with the ability to endure mechani-
cal and nonmechanical stresses, such as those encountered 
during DILI (Coulombe and Omary 2002). The importance 
of CK18 in the liver has been highlighted in CK18 knock-
out mice, with the absence of CK18 in hepatocytes leading 
to the spontaneous development of liver lesions (closely 
reflecting the morphological spectrum of steatohepatitis-
associated liver carcinogenesis), as well as liver tumours 
(Bettermann et al. 2016).
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CK18 may address the current gaps in knowledge 
and limitations left by traditional biomarkers 
for DILI
As well as providing a vital scaffold for epithelial cells of the 
liver, CK18 may help to address some of the current gaps in 
knowledge and limitations of traditional markers for DILI.
CK18 can identify the mechanism of hepatocellular 
injury
Traditional diagnostic markers provide limited insight 
into the mechanism of hepatocellular injury whereas, the 
level of both full-length CK18 and caspase-cleaved CK18 
(ccCK18) fragments in serum or plasma reflects the degree 
of necrotic hepatocellular injury and/or apoptosis (Church 
and Watkins 2017). During acute and chronic hepatocellular 
injury, necrotic cells passively release full-length CK18 into 
circulation due to the loss of cell membrane integrity (Caulín 
et al. 1997; Church and Watkins 2017; Schutte et al. 2004). 
In apoptosis, CK18 is targeted for proteolysis to facilitate the 
breakdown of the cytoskeleton and is released into circula-
tion as ccCK18 stable fragments (Caulín et al. 1997; Church 
and Watkins 2017; Fadok and Henson 1998; Schutte et al. 
2004). As demonstrated in Fig. 1, the CK18 protein con-
tains two caspase consensus sites, DALD and VEVD. The 
DALD motif is located in the C-terminal tail region and is 
targeted by caspases 3, 7 and 9 immediately following early 
apoptotic events such as the loss of membrane potential, 
presence of DNA fragmentation and release of cytochrome 
c (Fig. 1b, c) (Caulín et al. 1997; Ku et al. 1997; Leers et al. 
1999; Schutte et al. 2004). The VEVD motif is located in the 
central helical rod domain and is solely targeted by caspase 
6, with cleavage of the VEVD motif responsible for the final 
collapse of the CK18 cytoskeleton (Fig. 1c) (Ku et al. 1997; 
Schutte et al. 2004).
In clinical settings, both full-length CK18 and ccCK18 
fragment levels can be readily quantified by immunoassays. 
The locations of caspase cleavage and the molecular size 
of generated ccCK18 fragments have been identified by 
western blotting and liquid chromatography with tandem 
mass spectrometry (LC MS/MS) in both clinical and in vivo 
mouse models of DILI (Micha et al. 2008; Schutte et al. 
2004).
The detection of necrotic hepatocellular injury 
with full‑length CK18 can diagnose early‑stage DILI
The most significant advantage of utilising CK18, in particu-
lar full-length CK18, as a biomarker for DILI is that it can 
diagnose early-stage DILI (Church and Watkins 2017). The 
level of some traditional biomarkers, such as ALT and AST, 
are often elevated without the presence of any hepatocellular 
injury. Therefore, significant fold increases in ALT and/or 
AST levels (> 3–5 times the ULN) are considered adverse and 
indicative of potential hepatocellular injury. However, these 
significant elevations generally occur during the later stages 
of hepatocellular injury, when serum levels of these enzymes 
rise as liver function becomes increasingly impaired (Church 
and Watkins 2017). As serum levels of full-length CK18 are 
indicative of necrosis, detecting full-length CK18 in serum 
can indicate early necrotic hepatocellular injury (Church and 
Watkins 2017). However, given the ubiquitous expression of 
CK18, the abundance of full length CK18 needs to be stand-
ardised to either traditional diagnostic makers or potentially 
new biomarkers.
Identifying necrosis and apoptosis provides 
insight into the involvement of inflammation 
during hepatocellular injury
Identifying the mechanism of hepatocellular injury is key to 
assess the severity of DILI and enables the early administration 
and implementation of treatments and interventions which may 
improve prognosis. Necrosis is a process predominately driven 
by the innate immune response mediated by Toll-like recep-
tors and subsequently, pro- and anti-inflammatory cytokines 
such as tumour necrosis alpha (TNF-α) and interlukin-1 alpha 
(IL-1α) (Takeda and Akira 2015; Yang et al. 2015; Yilmaz 
2009). On the other hand, apoptosis is programmed cell death 
that predominately occurs through either activation of the 
TNF superfamily (extrinsic pathway) or the presence of free 
radicals (intrinsic pathway) (Caulín et al. 1997; Lorente 2018; 
Yilmaz 2009). In patients experiencing non-severe and severe 
idiosyncratic DILI, the serum level of pro- and anti-inflam-
matory cytokines in combination with serum levels of full-
length CK18 and ccCK18 fragments were shown to be able to 
determine which mechanism of hepatocellular injury, either 
necrosis or apoptosis, predominated in each patient group (Xie 
et al. 2019). In patients experiencing non-severe idiosyncratic 
DILI, serum levels of TNF-α, IL-1α, macrophage inflamma-
tory protein 1-beta (MIP-1β) and interferon gamma-induced 
protein 10 (IP-10) were significantly increased whilst serum 
levels of ccCK18 fragments were significantly decreased in 
comparison to patients experiencing severe idiosyncratic DILI 
(P < 0.05) (Table 1) (Xie et al. 2019). With these findings, it 
was concluded that necrotic hepatocellular injury was more 
predominate in patients experiencing non-severe idiosyncratic 
DILI compared to patients experiencing severe idiosyncratic 
DILI (Xie et al. 2019).
How does CK18 and ccCK18 compare to other novel 
biomarkers for DILI?
CK18 and ccCK18 are not the only novel biomarkers to 
diagnose DILI, with glutamate dehydrogenase (GLDH), 
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microRNA-122 (miRNA-122), macrophage colony stimu-
lating factor receptor (MCSFR) and osteopontin (OPN) also 
current candidates (Church et al. 2019). We have favoured 
both CK18 and ccCK18 over the before-mentioned novel 
biomarkers as they are more sensitive and specific in diag-
nosing early-stage DILI, can identify the mechanism of 
hepatocellular injury and have demonstrated a strong and 
consistent relationship with hepatocellular injury in clinic. 
In comparison, liver-specific miRNA-122 has demon-
strated large inter- and intra-patient variability, particularly 
amongst healthy patient cohorts, whilst GLDH has been 
recommended for use in certain clinical cohorts (Church 
et al. 2019; Flanigan et al. 2014). Similarly, both MCSFR 
and OPN are primarily inflammatory markers therefore, do 
not provide insight into the mechanism of hepatocellular 
injury and can also be indicative of wide-spread inflamma-
tion (Church et al. 2019).
Clinical research has identified a strong relationship 
between serum levels of full‑length CK18 
and ccCK18 fragments with hepatocellular injury
A summary of clinical studies that utilised the serum lev-
els of full-length CK18 and ccCK18 fragments to diagnose 
DILI are outlined in Table 1. Additionally, clinical studies 
investigating hepatocellular injuries non-alcoholic steato-
hepatitis (NASH), acute alcohol hepatitis (AAH) and hepa-
tocellular carcinoma (HCC) were also included. As evident 
Fig. 1  A schematic representa-
tion of full-length CK18 (a) 
and ccCK18 fragments (b, c). 
a Full-length CK18 contains 
two caspase consensus sites, 
VEVD and DALD. Full-length 
CK18 is recognised by the 
M5 and M6 antibody which is 
deployed in the M65 ELISA. 
The position of VEVD and 
DALD, as well as the molecular 
weight of the CK18 protein, is 
shown. b Following cleavage at 
the DALD site by caspases 3, 7 
and 9, two ccCK18 fragments 
are generated. Cleavage at the 
DALD site is recognised by 
the M30 antibody deployed in 
the M30 ELISA. The M6 and 
M5 antibody recognition sites 
remain conserved. c Following 
cleavage at both DALD and 
VEVD sites, three ccCK18 frag-
ments are generated. The M6, 
M5 and M30 antibody recogni-
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Table 1  A summary of recent clinical studies that utilised full-length CK18 and ccCK18 fragments to detect hepatocellular  injurya
Reference Hepatocellular injury CK18 quantification Findings
(Church et al. 2019) DILI (Various causative agents)
Serum samples were collected from the 
DILIN, PSTC and SAFE-T patient 
cohorts
Human M30 and M65 ELISA
(Peviva, Sweden)
Elevated serum full length CK18 and 
ccCK18 were significant predictors for 
death/liver transplantation (ROC AUC 
0.832, 95% CI 0.737–0.927 for full length 
CK18 and ROC AUC 0.778, 95% CI 
0.676–0.881 for ccCK18)
Serum full length CK18 and ccCK18 were 
more sensitive and predictive for death/
liver transplantation than AST (ROC 
AUC 0.700, 95% CI 0.587–0.814), ALT 
(ROC AUC 0.606, 95% CI 0.433–0.780) 
and ALP (ROC AUC 0.597, 95% CI 
0.433–0.760)
An AI was calculated for 162 patients 
utilising the ratio of serum full length 
CK18:ccCK18. AI was determined to 
be a significant predictor for death/liver 
transplantation (ROC AUC 0.761, 95% CI 
0.627–0.895)
Incorporating CK18 (in conjunction 
MCSFR) into MELD scoring increased 
the specificity of MELD scoring from 
0.738 to 0.889. Sensitivity remained the 
same at 0.933
Biomarkers such as CK18 and ccCK18 were 
most altered in APAP-induced hepatoxic-
ity
DILIN patients with Augmentin-induced 
hepatoxicity ↑ serum full length CK18 
and ccCK18 compared to SAFE-T patients 
(P = 0.028)
(Xie et al. 2019) Idiosyncratic DILI (Various causative 
agents)
Human M30 and M65 ELISA
(Peviva, Sweden)
Serum full length CK18 and ccCK18 ↑ 
in non-severe DILI and severe DILI vs 
control (P < 0.01)
Serum ccCK18 ↑ in severe DILI vs non-
severe DILI (P < 0.05)
Serum full length CK18 correlated with 
serum ALT (R2 = 0.632, P < 0.001) and 
AST (R2 = 0.754, P < 0.001) levels
Serum ccCK18 correlated with ALT 
(R2 = 0.554, P < 0.001) and AST 
(R2 = 0.657, P < 0.001) levels
No significant differences in serum full 
length CK18:ccCK18 ratio between 
control, non-severe DILI and severe DILI 
(P > 0.05)
(Vatsalya et al. 2019) AAH, AUD and NASH Human M30 and M65 ELISA
(Peviva, Sweden)
Serum full length CK18:ccCK18 ratio ↑ in 
severe AAH vs AUD (P < 0.05) and ↑ in 
severe AAH vs NASH (P < 0.05)
Serum full length CK18:ccCK18 ratio ↑ in 
moderate AAH vs NASH (P < 0.05)
Serum full length CK18 and ccCK18 were 
not correlated with ALT or AST levels 
(P > 0.05)
Serum Full length CK18:ALT ratio ↑ in 
AHH vs NASH (P < 0.001)
Serum ccCK18:ALT ratio ↑ in AHH vs 
NASH (P < 0.001)
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from Table 1, in each study serum levels of full-length 
CK18 and ccCK18 fragments were significantly increased 
in patients with hepatocellular injury compared to healthy 
controls (P < 0.05). In a handful of these studies, compari-
sons between the serum level of full-length CK18, ccCK18 
fragments and traditional diagnostic markers ALT and AST 
were made (Table 1) (Gonzalez-Quintela et al. 2006; Vat-
salya et al. 2019; Xie et al. 2019; Yagmur et al. 2007). The 
serum level of full-length CK18 and ccCK18 fragments 
were correlated to serum levels of ALT and AST in patients 
with chronic liver disease or idiosyncratic DILI (P < 0.05) 
(Table 1) (Gonzalez-Quintela et al. 2006; Xie et al. 2019; 
Yagmur et al. 2007). However, in patients with AAH, AUD 
or NASH, there was no correlation between serum level of 
full-length CK18 and ccCK18 fragments with ALT or AST 
(P < 0.01) (Table 1) (Vatsalya et al. 2019). These results sug-
gest the utility of both full-length CK18 and ccCK18 frag-
ments as biomarkers for hepatocellular injury is dependent 
on the type of hepatocellular injury.
The ratio of full-length CK18:ccCK18 was also 
determined to identify the proportion of hepatocellular 
injury attributable to apoptosis compared to necrosis 
(Church et al. 2019; Godin et al. 2015; Vatsalya et al. 
2019; Xie et al. 2019). In Table 1, it was identified that 
as the severity of hepatocellular injury increased, the 
ratio of CK18:ccCK18 also increased, indicating apop-
tosis became more prominent as the severity of injury 
increased (P < 0.05) (Church et al. 2019; Godin et al. 
2015; Vatsalya et al. 2019; Xie et al. 2019).
Furthermore, predictive risk modelling identified serum 
levels of both full-length CK18 and ccCK18 fragments 
(receiver operator characteristic area under the curve 
(ROC AUC) = 0.83 and 0.78, respectively) were more 
sensitive and specific in predicting the prognosis of death 
and liver transplantation compared to serum levels of 
AST, ALT and ALP (ROC AUC = 0.70, 0.61 and 0.60, 
respectively) (Church et al. 2019). Serum full length CK18 
was also found to be superior in distinguishing between 
mild and severe hepatocellular injury in chronic liver dis-
ease compared to serum levels of ALT, AST and ALP 
(P < 0.01) (Yagmur et al. 2007).
Table 1  (continued)
Reference Hepatocellular injury CK18 quantification Findings
(Godin et al. 2015) HCC and cirrhosis (Various causes) Human M30 and M65 ELISA
(Enzo Life Sciences, France)
Serum full length CK18 ↑ in HCC vs cir-
rhosis (P < 0.05)
Serum ccCK18 ↑ in HCC vs cirrhosis 
(P < 0.05)
No significant differences in serum full 
length CK18:ccCK18 ratio in HCC vs cir-





(Erastin, Doxorubicin and Sorafenib)
Human M30 and M65 ELISA
(Enzo Life Sciences, France)
Cells treated with Doxorubicin ↑ full length 
CK18 vs control (P < 0.05)
Cells treated with Erastin, Doxorubicin and 
Sorafenib ↑ ccCK18 vs control (P < 0.05)
Full length CK18:ccCK18 ratio ↑ with 
Doxorubicin vs control (P < 0.05)




Serum full length CK18 ↑ vs control 
(P < 0.001)
Serum full length CK18 more prominent in 
the early stage of CLD
Serum full length CK18 correlated 
with ALT (R2 = 0.602, P < 0.001), 
AST (R2 = 0.644, P < 0.001) and ALP 
(R2 = 0.397, P < 0.001)
Serum full length CK18 superior to ALT, 
AST and ALP in distinguishing between 
no or mild hepatic injury vs severe hepatic 
injury (P < 0.01)
a DILIN Drug-induced Liver Injury Network, samples were collected from patients within 6 months of DILI onset from multiple centres within 
the United States, PSTC: Predictive Safety Testing Consortium, SAFE-T Safer and Faster Evidence-based Translation, ELISA enzyme-linked 
immunosorbent assay, ROC AUC receiver operator characteristic, area under the curve, AI: apoptotic index of injury, MCSFR macrophage col-
ony-stimulating factor receptor, MELD scoring model for end-stage liver disease calculated as 9.57 ×  Loge(creatinine) + 3.78 ×  Loge (total bili-
rubin) + 11.2 ×  Loge (international normalised ratio) + 6.43; ↑:Significant increase, NASH Non-alcoholic steatohepatitis; vs: compared to, AAH 
acute alcoholic hepatitis; AUD alcohol use disorder; HCC hepatocellular carcinoma, CLD chronic liver disease
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There are various challenges and limitations 
surrounding the characterisation of CK18 
in preclinical models of DILI
Clinical research has demonstrated a strong relationship 
between serum levels of full-length CK18 and ccCK18 
fragments with DILI. However, to improve our interpreta-
tion of both full-length CK18 and ccCK18 fragments as 
biomarkers for DILI and for adding value in both clinical 
and preclinical settings, CK18 must be better character-
ised in preclinical models of DILI. Due to an array of 
challenges, only a handful of preclinical in vivo rat stud-
ies have investigated CK18 as a potential biomarker for 
hepatotoxicity. A summary of these in vivo rat studies 
and their limitations is outlined in Table 2. Of the current 
challenges and limitations surrounding the characterisa-
tion of CK18 as a biomarker of DILI in rat, the most 
significant is the lack of a species-specific quantitative 
CK18 assay.
At present, the serum and plasma level 
of full‑length CK18 and ccCK18 fragments cannot be 
quantified in an in vivo rat model of DILI
Due to the current lack of rat-specific quantitative assays, 
semi-quantitative and qualitative methods such as western 
blotting and LC MS/MS need to be used to identify the pres-
ence of full-length CK18 and ccCK18 fragments in in vivo 
rat models of DILI. In clinical research, the serum level of 
full-length CK18 and ccCK18 fragments is quantified using 
the M65 and/or M30 ELISA (Fig. 1 and Table 1). The M65 
ELISA, utilizing the M5 and M6 CK18 monoclonal anti-
bodies, detects binding to epitopes of the CK18 protein that 
are present in both full-length CK18 and ccCK18 fragments 
(Fig. 2B, C) (Kramer et al. 2004; Olofsson et al. 2009). 
Hence, the M65 ELISA can quantify the total level of CK18 
(U/L), measuring total cell death by necrosis (full-length 
CK18) and apoptosis (ccCK18 fragments) (Kramer et al. 
2004; Olofsson et al. 2009). Currently, M65 is only specific 
for human CK18 and although a number of rat-specific M65 
ELISAs have recently been released for commercial use, 
their performance is yet to be reported in the literature.
Table 2  A summary of in vivo rat models that utilised full-length CK18 and ccCK18 fragments to detect hepatocellular  injury2
b NASH non-alcoholic steatohepatitis, ELISA enzyme-linked immunosorbent assay,↑Significant increase, vs: compared to, IHC immunohisto-
chemistry, RT Q-PCR real-time quantitative polymerase chain reaction
Study details CK18 quantification Findings Limitations of the study
(Dai et al. 2020)




Serum ccCK18 ↑ in NASH vs 
control (P = 0.035)
Serum ccCK18 correlated with 
liver pathological scores 
(R2 = 0.631, P = 0.008)
No correlation between serum 
ALT levels and liver pathological 
scores (P = 0.055)
Human M30 ELISA has 100-fold 
lower efficiency in rats
Intra-assay variability of the M30 
ELISA
(Maliver et al. 2017)




Serum ccCK18 ↑ at 400 and 
750 mg/kg clofibrate dose vs 
control (P < 0.05 and P < 0.01)
Serum ALT levels ↑ at 200, 400 
and 750 mg/kg clofibrate dose vs 
control (P < 0.01, P < 0.001 and 
P < 0.001, respectively)
Correlation between liver biomark-
ers and hepatocyte hypertrophy 
was not conducted
Human M30 ELISA has 100-fold 
lower efficiency in rats
Intra-assay variability of the M30 
ELISA
Clofibrate is not a commonly used 
in vivo model of DILI
(Kakehashi et al. 2009)
Fisher 344 rats with DILI 
[N-Nitrosodimethylamine (DEN) 
and Phenobarbital (PB)]
IHC and RT Q-PCR IHC demonstrated full length 
CK18 ↑ DILI (DEN + PB) vs 
control (P < 0.001)
Full length CK18 mRNA ↑ in 
DILI (DEN + PB) vs control 
(P < 0.05)
ccCK18 was not investigated
RT Q-PCR is indicative of gene 
expression. No protein analysis
IHC is semi-quantitative
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The M30 ELISA is also used in clinical research and this 
quantifies the serum level of ccCK18 fragments (Olofsson 
et al. 2009; Pimentel et al. 2016). The M30 antibody rec-
ognises the neo-epitope generated following cleavage at 
the DALD site in human CK18 at amino acid position 393 
(Fig. 2B, C) (Pimentel et al. 2016). The M30 ELISA solely 
quantifies apoptosis and by examining both M65 and M30 
ELISAs in parallel, the degree of necrotic hepatocellular 
injury and apoptosis can be determined. The region recog-
nised by the M30 ELISA is 87% conserved between human 
and mouse CK18 (Olofsson et al. 2009). However, research 
has shown the peptide used to compete for CK18 in the M30 
ELISA has a 100-fold lower efficiency for both mouse and 
rat CK18 due to changes in the amino acid sequence as dem-
onstrated in Fig. 2 (Olofsson et al. 2009).
Additionally, poor intra-assay variability is a common 
problem identified between M30 ELISAs. Pimentel et al. 
(2016) measured serum levels of ccCK18 fragments in a 
cohort of NASH patients using two commercially available 
M30 ELISA kits (Pimentel et al. 2016). It was determined 
that there was no significant correlation between serum 
levels of ccCK18 fragments between the two M30 ELISA 
kits (P = 0.86, r = 0.01) (Pimentel et al. 2016). Furthermore, 
binary logistic regression only identified the serum level of 
ccCK18 fragments quantified by one of the M30 ELISAs to 
be a significant predictor for NASH (Pimentel et al. 2016).
Until a rat-specific M65 ELISA is optimised, semi-quan-
titative and qualitative methods will need to be utilised to 
detect full-length CK18 and ccCK18 fragments in an in vivo 
rat model of DILI. The significant disadvantage of using 
semi-quantitative and qualitative methods is they cannot be 
used to compare values across studies or to compare the full 
length CK18 to ccCK18 in a meaningful way. Therefore, to 
implement both full-length CK18 and ccCK18 fragments 
as routine biomarkers for DILI in preclinical settings, it 
is imperative a rat-specific M65 ELISA is optimised and 
a rat-specific M30 ELISA is developed. In addition, prot-
eomic-based analysis such as LC MS/MS and SWATH MS 
(sequential window acquisition of all theoretical fragment 
ion spectra mass spectrometry) may also be useful to quan-
titate the levels of full length CK18 and ccCK18 fragments. 
However, these forms of analyses will only be beneficial 
once rat CK18 protein has been characterised and added 
to the respective protein libraries. Once full length CK18 
and ccCK18 fragments are able to be quantified, the next 
step is selecting the appropriate in vivo rat model of DILI. 
However, this in itself has its own challenges.
The commonly used acetaminophen (APAP) in vivo 
model of DILI has notable disadvantages in rats
The two most common model hepatotoxins used in in vivo 
research are APAP and carbon tetrachloride  (CCl4) never-
theless, both models have specific limitations in rats, the 
species commonly used in preclinical drug safety testing 
(McGill and Jaeschke 2019). APAP is the preferred in vivo 
model of DILI due to its clinical relevance and the fact that 
the mechanism of hepatocellular injury induced by APAP is 
well understood (McGill and Jaeschke 2019; McGill et al. 
2012b). APAP overdose is a leading cause of acute liver 
failure in several Western Countries, including the United 
Kingdom and United States, with hepatocellular injury 
mediated by NAPQI (Bernal 2003; McGill and Jaeschke 
2019; Ostapowicz et al. 2002). The conversion of APAP to 
NAPQI is catalysed by cytochrome P450 enzymes (McGill 
et al. 2012a; Xie et al. 2015). NAPQI subsequently binds 
to sulfhydryl groups on glutathione (GSH) and proteins, 
depleting glutathione and increasing cell susceptibility to 
oxidative stress (McGill et al. 2012a; Xie et al. 2015). Addi-
tionally, NAPQI binds to mitochondrial proteins, inhibiting 
mitochondrial respiration and leading to the development 
of mitochondrial oxidative stress (Cover et al. 2005; Meyers 
et al. 1988).
The most significant concern of using APAP in in vivo 
rat models of DILI is that rats are more resistant to APAP-
induced hepatocellular injury (McGill et al. 2012b). When 
administered comparable doses of APAP, the degree of hepa-
tocellular damage and hepatotoxicity in rats is limited and, 
in some instances, non-existent, compared to the degree of 
hepatocellular damage observed in humans (McGill et al. 
2012b). The mechanism of APAP toxicity in humans is 
more similar to mice, with doses of ≥ 150 mg/kg inducing 
DILI in both species (Boxill et al. 1958; Eder 1964; Jaeschke 
et al. 2014; McGill et al. 2012b). However, some reports in 
Sprague–Dawley and Fisher rats treated with APAP at 1–2 g/
kg suggest there was no evidence of oxidative stress with no 
significant differences in GSH/oxidised glutathione (GSSG) 
percentage following APAP treatment (P > 0.05) (McGill et al. 
2012b). Mitochondrial APAP-protein adduct levels were also 







Fig. 2  The neo-epitope produced in human, chimp, rat, mouse 
and canine CK18 following cleavage at the DALD cleavage site by 
caspases 3, 7 and 9. The M30 antibody recognises the human neo-
epitope however, it has a 100-fold lower efficiency for the rat and 
mouse neo-epitope
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not significantly different compared to control treated rats 
(P < 0.05) (McGill et al. 2012b). Furthermore, no histologi-
cal hepatocellular injury was identified in these rats following 
APAP treatment (McGill et al. 2012b). It is unclear why rats 
are resistant to APAP-induced hepatocellular injury but, it is 
crucial that a significant degree of hepatocellular injury is pre-
sent to adequately investigate the relationship between serum 
levels of full-length CK18 and ccCK18 fragments with DILI.
CCl4 is also a commonly used in vivo model for DILI 
research.  CCl4 is a chlorinated hydrocarbon with high doses of 
 CCl4 ≥ 1 mL/kg inducing hepatocellular injury that resembles 
intrinsic DILI (McGill and Jaeschke 2019). Unlike APAP, the 
mechanism of  CCl4 hepatocellular injury is not well under-
stood but, is believed to be dependent on the reactive metabo-
lite trichloromethyl radical  (CCl3) (McGill and Jaeschke 2019; 
Weber et al. 2003).  CCl4 is converted by cytochrome P450 to 
 CCl3, which subsequently binds to proteins, DNA and lipids, 
leading to mitochondrial and oxidative stress (McGill and Jae-
schke 2019). Necrosis induced by  CCl4 is limited to areas of 
high cytochrome P450 concentration and expression, such as 
the centrilobular area of the liver (Weber et al. 2003). This 
specific pattern of hepatocellular injury is not consistent with 
other forms of DILI but, most importantly, as  CCl4 is not a 
pharmaceutical drug, it may be difficult to translate the results 
of a  CCl4 in vivo rat model of DILI (Slater 1966; Weber et al. 
2003).
Another potential but less common in vivo rat model for 
DILI is methotrexate (MTX). MTX is an antimetabolite drug 
used for the treatment and maintenance of inflammatory dis-
eases (low-dose MTX, 7.5–25 mg daily) and forms part of 
many chemotherapy regimens (high-dose MTX, 200–800 mg 
bolus doses) (Sotoudehmanesh et al. 2010; Whirl-Carrillo 
et al. 2012). Hepatocellular injury is the most common adverse 
effect of high-dose MTX, with hepatocellular damage local-
ised in liver sinusoidal endothelial cells (Sotoudehmanesh 
et al. 2010). High-dose MTX in vivo significantly elevates 
ALT and AST levels, increases expression of fibrin and, leads 
to severe steatosis, sinusoidal dilation, as well as, moderate 
inflammation and necrosis (Ewees et al. 2019). Given the clini-
cal nature of MTX and strong, reproducible evidence MTX 
induces severe hepatocellular injury in vivo, MTX may be 
favoured over traditional APAP and  CCl4 in vivo rat models 
of DILI.
In addition to selecting the appropriate in vivo rat model of 
DILI, one must also understand how liver regeneration in the 
selected model may affect the release of full-length CK18 and 
ccCK18 fragments into circulation.
Liver regeneration in the selected in vivo model 
of DILI may affect the kinetics of full‑length CK18 
and ccCK18 fragments
Liver regeneration in the chosen in vivo rat model of DILI 
can also be considered. The liver has the unusual capac-
ity to repair and regenerate following hepatocellular injury 
and partial hepatectomy (Clemens et al. 2019). Upon DILI, 
an intricate signalling process mediated by cytokines, 
chemokines and growth factors is triggered to stimulate 
healthy hepatocytes surrounding areas of necrosis to enter 
the cell cycle and undergo division (Apte et al. 2009; Clem-
ens et al. 2019; Leevy et al. 1959). Following APAP-induced 
hepatocellular injury, TNF-α and interleukin-6 (IL-6), as 
well as ß-catenin, endothelial growth factor receptor (EGFR) 
and vascular endothelial growth factor (VEGF), play a vital 
role in liver regeneration (Bhushan and Apte 2019; Dona-
hower et al. 2006). Similarly, TNF-α, IL-6 and hepatocel-
lular growth factor (HGF) are also involved in liver regen-
eration following  CCl4-induced hepatocellular injury (Burr 
et al. 1998; Clemens et al. 2019; Scheving et al. 2015). Liver 
regeneration can prevent the progression of DILI therefore, 
it is critical a dose of APAP or  CCl4 is administered that 
inhibits liver regeneration and leads to the rapid progression 
of hepatocellular injury (Mehendale 1991, 2005).
The tissue specificity of CK18 needs to be 
established in both preclinical and clinical models
CK18 is highly concentrated in hepatocytes and cholangio-
cytes however, as the protein plays a vital role in maintain-
ing the cytoskeleton of epithelial cells, it can also be found 
in epithelial cells lining other organs (Church et al. 2019; 
Church and Watkins 2017). Two-dimensional gel electro-
phoresis observed CK18 in substantial amounts in simple 
cuboidal epithelial cells lining the pancreatic ducts and 
kidney tubules, as well as simple columnar epithelial cells 
lining the mucosa of the small intestine and colon (Ku et al. 
1999; Moll et al. 1982). The pancreas, kidneys, small intes-
tine and colon are all known to be targets of drug-induced 
injury, particularly following therapy with angiotensin-con-
verting enzyme inhibitors (pancreas), non-steroidal anti-
inflammatories (kidneys) and cytotoxic drugs (small intes-
tine and colon). As CK18 has been identified in a handful of 
susceptible organs, in some instances of multi-organ drug-
induced toxicity, it may be difficult to determine if serum 
levels of full-length CK18 and ccCK18 fragments are only 
reflective of DILI or, reflect an array of drug-induced inju-
ries (Church and Watkins 2017; Tajima et al. 2019).
CK18 is also expressed by a variety of adenocarcinomas 
such as those of the lung, pancreas, prostate, colon and rec-
tum (Kramer et al. 2004). During cytotoxic drug therapy, 
CK18 is released from tumour cells and plasma levels of 
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both full-length CK18 and ccCK18 fragments are com-
monly utilised to evaluate clinical progression and tumour 
cell death (Kramer et al. 2004). This may present challenges 
when one or multiple cytotoxic drugs are used in therapy 
that also induce DILI, such as irinotecan or oxaliplatin (Rob-
inson et al. 2012).
As such, it is important for both preclinical and clinical 
models to determine the level of CK18 present in organs 
such as the kidney and small intestine and if full-length 
CK18 and/or ccCK18 fragments are released during drug-
induced injury from these organs. This can be addressed 
in preclinical models of drug-induced kidney, pancreatic 
and gastrointestinal injury. It may be necessary to define a 
predetermined ratio or percentage of full-length CK18 and 
ccCK18 fragments that can be attributed to hepatocellular 
injury (Church and Watkins 2017). Nevertheless, CK18 may 
still address current gaps in knowledge and limitations, in 
particular, forming part of a biomarker panel that can inform 
on necrotic and apoptotic hepatocellular injury and tissue 
specificity.
Conclusions
DILI is a frequent and serious adverse reaction that can 
occur during preclinical and clinical drug therapy and for 
which new biomarkers are required. CK18 is a potential bio-
marker for DILI and has some desirable properties that may 
help in detection of early-stage DILI and in the identification 
of the mechanism of hepatocellular injury. CK18 has been 
applied as a biomarker for DILI in clinical research, demon-
strating both full-length and cleaved versions of the protein 
are accurate and sensitive in diagnosing DILI. However, for 
CK18 to be applied as a biomarker for DILI preclinically, 
it needs to be characterised in an in vivo rat model of DILI, 
due to being the routine species used in preclinical drug 
safety assessment. The challenges of characterising CK18 in 
an in vivo rat model of DILI are well-documented, but, once 
the appropriate in vivo model of DILI has been identified, 
it will be possible to undertake validation work on recently 
released rat-specific M65 ELISAs, and determine the speci-
ficity of CK18 to hepatocellular injury. This review has pro-
vided evidence to support the characterisation of CK18 in 
an in vivo rat model of DILI, and to investigate the potential 
translation of CK18 as a routinely used biomarker for DILI 
in clinical settings.
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